Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 1 - 18 |
| Updated: | 9/30/2018 |
| Start Date: | September 2015 |
| End Date: | June 2019 |
| Contact: | Jeffrey Feinstein, MD, MPH |
| Email: | jeff.feinstein@stanford.edu |
The purpose of this study is to test the efficacy of treprostinil in the perioperative
non-fenestrated, extracardiac Fontan patients in order to reduce duration of chest tube
drainage (in days).
The Fontan operation is performed for patients with single ventricle physiology as the final
palliation to create a series circulation, with passive systemic venous return to the
pulmonary arteries and the single ventricle solely providing systemic output.
Patients undergoing extracardiac Fontan tend to have elevation of Fontan pressures
immediately following the operation with inflammation from surgery requiring additional fluid
administration to maintain blood pressure. Increased Fontan pressures and fluid overload lead
to prolonged chest tube drainage.
The hypothesis is that treprostinil, a prostacyclin drug that dilates the pulmonary arteries,
will improve immediate postoperative Fontan pressures. Treprostinil is not FDA approved for
this use. Anecdotally and in a small case series, prostacyclin therapy has been shown to
assist in transitioning patients off nitric oxide. The investigators believe that this
improvement in hemodynamics will decrease duration of chest tube drainage resulting in a
shorter length of hospital stay.
non-fenestrated, extracardiac Fontan patients in order to reduce duration of chest tube
drainage (in days).
The Fontan operation is performed for patients with single ventricle physiology as the final
palliation to create a series circulation, with passive systemic venous return to the
pulmonary arteries and the single ventricle solely providing systemic output.
Patients undergoing extracardiac Fontan tend to have elevation of Fontan pressures
immediately following the operation with inflammation from surgery requiring additional fluid
administration to maintain blood pressure. Increased Fontan pressures and fluid overload lead
to prolonged chest tube drainage.
The hypothesis is that treprostinil, a prostacyclin drug that dilates the pulmonary arteries,
will improve immediate postoperative Fontan pressures. Treprostinil is not FDA approved for
this use. Anecdotally and in a small case series, prostacyclin therapy has been shown to
assist in transitioning patients off nitric oxide. The investigators believe that this
improvement in hemodynamics will decrease duration of chest tube drainage resulting in a
shorter length of hospital stay.
In order to understand the effect of treprostinil on Fontan patients, this study has two
parts:
1. reactivity testing with inhaled treprostinil in the cardiac catheterization lab for
pre-Fontan patients undergoing routine catheterization in anticipation of the Fontan
operation;
2. perioperative use of subcutaneous treprostinil starting immediately pre-op until
postoperative day #7 to improve immediate postoperative hemodynamics and ultimately
reduce overall length of hospital stay.
The investigators hope to learn how pulmonary vasodilator therapy affects and/or improves
post- operative hemodynamics following the Fontan operation. This knowledge would be very
important in the care of single ventricle patients following the Fontan operation if there is
improvement of immediate outcomes and reduction of hospital length of stay. On a broader
scale, if the use of treprostinil in perioperative Fontan patients can achieve the same
results other centers achieve with the use of a fenestration this may have wide scale
implications in the nationwide treatment of Fontan patients.
parts:
1. reactivity testing with inhaled treprostinil in the cardiac catheterization lab for
pre-Fontan patients undergoing routine catheterization in anticipation of the Fontan
operation;
2. perioperative use of subcutaneous treprostinil starting immediately pre-op until
postoperative day #7 to improve immediate postoperative hemodynamics and ultimately
reduce overall length of hospital stay.
The investigators hope to learn how pulmonary vasodilator therapy affects and/or improves
post- operative hemodynamics following the Fontan operation. This knowledge would be very
important in the care of single ventricle patients following the Fontan operation if there is
improvement of immediate outcomes and reduction of hospital length of stay. On a broader
scale, if the use of treprostinil in perioperative Fontan patients can achieve the same
results other centers achieve with the use of a fenestration this may have wide scale
implications in the nationwide treatment of Fontan patients.
Inclusion Criteria:
- Pediatric patient undergoing Fontan operation and/or pre-Fontan cardiac
catheterization at Lucile Packard Children's Hospital (LPCH)
Exclusion Criteria:
- Platelet count < 50K (treprostinil can act as a platelet inhibitor and this may place
patient at additional risk of bleeding if already thrombocytopenic)
- Dermatologic condition that renders the patient unable to tolerate a subcutaneous
infusion (can still take part in inhaled vasodilator testing during cardiac
catheterization)
- Currently receiving any vasodilator therapy specifically for the purpose of pulmonary
vsasodilation (phosphodiesterase type 5 inhibitor, endothelia receptor antagonist
and/or prostacyclin).
We found this trial at
1
site
Palo Alto, California 94304
Principal Investigator: Jeffrey Feinstein, MD, MPD
Click here to add this to my saved trials
